Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Nucor Corporation (NUE) Price & Performance

Mesoblast LimitedTrade
Nucor CorporationTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Nucor Corporation — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while Nucor Corporation trades at $269.69 (market cap $61.93B). The key difference: Nucor Corporation is far larger — about 28× Mesoblast Limited's market cap, and Nucor Corporation pays a 0.82% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESONUE
Market Cap
$2.21B$61.93B
Sector
TechnologyBasic Materials
52-Week High
$20.96$274.74
52-Week Low
$12.88$131.78
Enterprise Value
$2.21B$66.34B
Dividend Yield
0.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Nucor Corporation

Nucor (NUE) trades at $269.50, down 1.86% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings with EPS of $4.84 beating estimates of $4.46, driven by record steel mill shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections indicating $36.1B revenue and improved margins. Analyst consensus remains positive with 59% buy ratings and a $279.63 price target, representing 3.8% upside potential.

Nucor presents a compelling investment case with earnings momentum, favorable analyst sentiment, and technical strength. Key opportunities include continued demand recovery and operational efficiency gains. However, risks include cyclical steel industry exposure, tariff policy uncertainties, and declining operating cash flow trends from 2022 peaks. The stock offers moderate upside to consensus targets but faces macroeconomic headwinds affecting industrial demand.

Returns comparison

Trailing returns across standard periods

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Nucor Corporation

Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.

Read more on NUE